Skip NavigationSkip to Content
Return Return to Search Results

Pharmacogenomics and cancer stem cells: a changing landscape?

  1. Author:
    Crea, F.
    Duhagon, M. A.
    Farrar, W. L.
    Danesi, R.

  2. Author Address

    [Crea, F; Danesi, R] Univ Pisa, Dept Internal Med, Div Pharmacol, Pisa, Italy. [Duhagon, MA] Univ Republica, Fac Med, Dept Genet, Lab Interacc Mol, Montevideo, Uruguay. [Farrar, WL] NCI, Lab Canc Prevent, Canc Stem Cell Sect, Frederick, MD 21701 USA.;Danesi, R (reprint author), Univ Pisa, Dept Internal Med, Div Pharmacol, Pisa, Italy;r.danesi@med.unipi.it
    1. Year: 2011
    2. Date: Aug
  2. Journal: Trends in Pharmacological Sciences
    1. 32
    2. 8
    3. Pages: 487-494
  4. Type of Article: Review
  5. ISSN: 0165-6147
  1. Abstract:

    Pharmacogenomics in oncology holds the promise to personalize cancer therapy. However, its clinical application is still limited to a few genes, and, in the large majority of cancers, the correlation between genotype and clinical outcome has been disappointing. One possible explanation is that current pharmacogenomic studies do not take into account the emerging role of cancer stem cells (CSCs) in drug sensitivity and resistance. CSCs are a subpopulation of cells driven by specific signal-transduction pathways, but genetic variants affecting their activity are generally neglected in current pharmacogenomic studies. Moreover, in several malignancies, CSCs represent a rare sub-population; therefore, whole tumor profiling might mask CSC gene expression patterns. This article reviews current evidence on CSC chemoresistance and shows how common genetic variations in CSC-related genes may predict individual response to anti-cancer agents. Furthermore, we provide insights into the design of pharmacogenomic studies to address the clinical usefulness of CSC genetic profiling.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.tips.2011.03.010
  3. View record in Web of Science®
  4. WOS: 000293932500005

Library Notes

  1. Fiscal Year: FY2010-2011
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel